In this context, preclinical research has demonstrated that BC cells expressing BRCA1/2 mutations exhibit sensitivity to PARP-1 inhibition due to their dependence on PARP-1 activity for DNA repair [92, 93]. The gene discussed is PARP1; the disease is breast cancer.